Residual Gastric ContentsNCT07616908
Effect of Miralax NPO Time on Residual Gastric Volumes and Bowel Preparation
A study testing Stopping Miralax ingestion 4 hours prior to anesthesia induction, Stopping Miralax ingestion 6 hours prior to anesthesia induction and Stopping Miralax ingestion 2 hours prior to anesthesia induction in people with Residual Gastric Contents and Polyethylene Glycol, run by Stanford University.
Trial summary
The goal of this clinical trial is to assess differences in residual gastric volumes after stopping Miralax ingestion at different time points (2, 4, 6 hours) prior to anesthesia induction and compare it to the control (current institutional standard of care where no Miralax is given on the day of surgery). Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Residual Gastric Contents, Polyethylene Glycol
- What is being tested?
- Stopping Miralax ingestion 4 hours prior to anesthesia induction, Stopping Miralax ingestion 6 hours prior to anesthesia induction and Stopping Miralax ingestion 2 hours prior to anesthesia induction
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- Jul 2026to Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients undergoing both EGD and colonoscopy
- Use of Miralax for cleanout
- Patients <19 years old
Who cannot join
- Patients with a history of delayed gastric emptying (eg diabetic, GLP-1 intake)
- Patients with a history of gastric sleeve surgery
- Use of Golytely for cleanout
- Emergent EGD/colonoscopies
- EGD/colonoscopies for foreign body removal and/or decompression
- Known neurologic compromise
Show all 9Show fewer
- Presence of pre-existing ostomy, short bowel syndrome, gastric retention, intestinal obstruction, ileus, bowel perforation, toxic colitis, toxic megacolon, swallowing difficulties
- Pre-existing electrolyte derangements
- Allergy to Miralax
About this study
The goal of this clinical trial is to assess differences in residual gastric volumes after stopping Miralax ingestion at different time points (2, 4, 6 hours) prior to anesthesia induction and compare it to the control (current institutional standard of care where no Miralax is given on the day of surgery).
- Conditions
- Residual Gastric Contents, Polyethylene Glycol
- Being tested
- Stopping Miralax ingestion 4 hours prior to anesthesia induction, Stopping Miralax ingestion 6 hours prior to anesthesia induction, Stopping Miralax ingestion 2 hours prior to anesthesia induction, Control
- Keywords
- residual gastric volume, miralax, polythylene glycol, gastric POCUS, pediatric, EGD, colonoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stopping Miralax ingestion 4 hours prior to anesthesia inductionBehavioural
Stopping Miralax ingestion 4 hours prior to anesthesia induction
Stopping Miralax ingestion 6 hours prior to anesthesia inductionBehavioural
Stopping Miralax ingestion 6 hours prior to anesthesia induction
Stopping Miralax ingestion 2 hours prior to anesthesia inductionBehavioural
Stopping Miralax ingestion 2 hours prior to anesthesia induction
ControlBehavioural
Miralax will not be given on the day of surgery
| Study group | Role | What they receive |
|---|---|---|
| 4hr NPO | Active comparator | Miralax will be stopped 4 hours prior anesthesia induction Receives: Behavioral: Stopping Miralax ingestion 4 hours prior to anesthesia induction |
| 6hr NPO | Active comparator | Miralax will be stopped 6 hours prior anesthesia induction Receives: Behavioral: Stopping Miralax ingestion 6 hours prior to anesthesia induction |
| 2hr NPO | Active comparator | Miralax will be stopped 2 hours prior anesthesia induction Receives: Behavioral: Stopping Miralax ingestion 2 hours prior to anesthesia induction |
| Control | Active comparator | Miralax will not be given day of surgery Receives: Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Residual gastric volume as measured by EGD
Measured: To be performed at the start of the EGD immediately after anesthesia induction.
Secondary outcomes (3)
Preoperative gastric POCUS volume assessment
Measured: Performed prior to anesthesia induction
Effectiveness of colonoscopy cleanout
The effectiveness of colonoscopy cleanout will be assessed by the Boston Bowel Preparation Scale (BBPS).
Measured: Performed during the colonoscopy portion following upper GI endoscopy (EGD)
Incidence of aspiration on induction and perioperative aspiration
Measured: On anesthesia induction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2026
- Study startJul 2026 (estimated)
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Residual Gastric ContentsStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stephanie Jiaying Pan, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07616908
- Sponsor's protocol ID
- 86683
- Status last verified
- Jul 2026
- First submitted
- 17 May 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Miralax NPO Time on Residual Gastric Volumes and Bowel Preparation
- ClinicalTrials.gov ID
- NCT07616908
- Acronym / sponsor ID
- 86683
- Conditions
- Residual Gastric Contents, Polyethylene Glycol
- Keywords
- residual gastric volume, miralax, polythylene glycol, gastric POCUS, pediatric, EGD, colonoscopy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 1 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to assess differences in residual gastric volumes after stopping Miralax ingestion at different time points (2, 4, 6 hours) prior to anesthesia induction and compare it to the control (current institutional standard of care where no Miralax is given on the day of surgery).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 4hr NPO | Active comparator | Behavioral: Stopping Miralax ingestion 4 hours prior to anesthesia inductionMiralax will be stopped 4 hours prior anesthesia induction |
| 6hr NPO | Active comparator | Behavioral: Stopping Miralax ingestion 6 hours prior to anesthesia inductionMiralax will be stopped 6 hours prior anesthesia induction |
| 2hr NPO | Active comparator | Behavioral: Stopping Miralax ingestion 2 hours prior to anesthesia inductionMiralax will be stopped 2 hours prior anesthesia induction |
| Control | Active comparator | Behavioral: ControlMiralax will not be given day of surgery |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Patients undergoing both EGD and colonoscopy
- Use of Miralax for cleanout
- Patients <19 years old
Key exclusion criteria (9 listed)
- Patients with a history of delayed gastric emptying (eg diabetic, GLP-1 intake)
- Patients with a history of gastric sleeve surgery
- Use of Golytely for cleanout
- Emergent EGD/colonoscopies
- EGD/colonoscopies for foreign body removal and/or decompression
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stopping Miralax ingestion 4 hours prior to anesthesia inductionStopping Miralax ingestion 4 hours prior to anesthesia induction | Behavioural | 4hr NPO |
| Stopping Miralax ingestion 6 hours prior to anesthesia inductionStopping Miralax ingestion 6 hours prior to anesthesia induction | Behavioural | 6hr NPO |
| Stopping Miralax ingestion 2 hours prior to anesthesia inductionStopping Miralax ingestion 2 hours prior to anesthesia induction | Behavioural | 2hr NPO |
| ControlMiralax will not be given on the day of surgery | Behavioural | Control |
Primary outcome
Residual gastric volume as measured by EGD
Time frame: To be performed at the start of the EGD immediately after anesthesia induction.
3 secondary outcomes
Preoperative gastric POCUS volume assessment
Time frame: Performed prior to anesthesia induction
Effectiveness of colonoscopy cleanout
Time frame: Performed during the colonoscopy portion following upper GI endoscopy (EGD)
Incidence of aspiration on induction and perioperative aspiration
Time frame: On anesthesia induction
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Residual Gastric Contents
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Not yet recruitingObservational study
Preoperative Gastric Volume and High-Risk Gastric Content in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (DM), Gastric Ultrasound
Recruiting
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
Pulmonary Aspiration
Recruiting
Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists
Residual Gastric Contents, Pulmonary Aspiration of Gastric Contents
Recruiting
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
Fasting, Gastric Emptying
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Stopping Miralax ingestion 4 hours prior to anesthesia induction, Stopping Miralax ingestion 6 hours prior to anesthesia induction and Stopping Miralax ingestion 2 hours prior to anesthesia induction in people with Residual Gastric Contents and Polyethylene Glycol, run by Stanford University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Residual gastric volume as measured by EGD (time frame: To be performed at the start of the EGD immediately after anesthesia induction.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.